Business Wire

61. Tripos International Completes Acquisition Of Pharsight Corporation 11/3/2008
    Tripos International, the leading provider of drug discovery informatics products and services, today announced that it has completed the acquisition of Pharsight Corporation, a leader in software, strategic and regulatory services designed to optimize clinical drug development
62. Aureus Pharma To Participate In A European Consortium For Drug Cardiac Toxicity 10/30/2008
    Aureus Pharma, a leading provider of knowledge management solutions that accelerate life science discovery, announced today that they will participate in a consortium along with a number of industrial and academic research teams in a European Commission funded project entitled “preDiCT: Computational Prediction of Drug Cardiac Toxicity”
63. National Cancer Institute Selects CambridgeSoft To Support Chemical Biology Consortium 9/29/2008
    The National Cancer Institute has selected the ChemBioOffice Enterprise suite as the single solution Informatics platform to support a highly collaborative drug discovery partnership, the Chemical Biology Consortium
64. ACADIA Pharmaceuticals To Present At The JMP Securities Healthcare Focus Conference On October 6, 2008 9/29/2008
    ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the JMP Securities Healthcare Focus Conference on Monday, October 6, 2008, at 1:00 p.m
65. Drug Discovery Research Turns To Biomarkers 9/25/2008
    The total drug discovery market in Western Europe was worth $17.40 billion in 2007, and Frost & Sullivan expects this to grow at a compound annual growth rate of 13.5% to reach $42.08 billion by 2014
66. Curis Announces Dosing Of First Patient In Phase I Clinical Trial Of CUDC-101 8/26/2008
    Curis, Inc.a drug development company focused on developing next generation proprietary targeted medicines for cancer treatment today announced that the first patient has been treated in a Phase I clinical trial of CUDC-101, a first-in-class small molecule drug candidate that has been designed as an inhibitor of epidermal growth factor receptor
67. Cellumen And Mitsubishi Tanabe Pharma Corporation Collaborate In Discovery Toxicology 8/19/2008
    Cellumen, Inc., a discovery toxicology company,announced an agreement with Mitsubishi Tanabe Pharma Corporation, one of the leading pharmaceutical companies in Japan, to develop panels of biomarkers that identify toxicity early in the drug development process
68. Mallinckrodt Baker And Rubicon Research Sign Agreement For Performance Excipient Development 8/18/2008
    Covidien, a leading global provider of healthcare products, today announced that its Mallinckrodt Baker business has entered into a licensing and commercialization agreement with drug development research specialist Rubicon Research